Trial Profile
Withdrawal response of patients with Early-Stage (GLOD stage I-II) Chronic Obstructive Pulmonary Disease after tiotropium bromide (Spiriva) treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2018
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 05 Aug 2018 New trial record